eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | autosomal dominant polycystic kidney disease |
| Comorbidity | C0158683|polycystic liver disease |
| Sentences | 6 |
| PubMedID- 23355918 | A review of literature on polycystic liver disease in patients with adpkd and current management strategies are presented. |
| PubMedID- 24987537 | Combined liver and kidney transplant in a patient with budd-chiari syndrome secondary to autosomal dominant polycystic kidney disease associated with polycystic liver disease: report of a case with a 9-year follow-up. |
| PubMedID- 23499726 | Background & aims: polycystic liver disease (pld) is associated with autosomal dominant polycystic kidney disease (adpkd) or autosomal dominant polycystic liver disease (pcld). |
| PubMedID- 22475206 | Adpdk subjects are screened for eligibility, and 43 adpkd patients with symptomatic polycystic liver disease and egfr > 30 ml/min (mdrd formula) will be included. |
| PubMedID- 22773240 | Background: we showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.(r) (octlar((r))) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (pld) and liver growth in patients with severe isolated pld. |
| PubMedID- 25369108 | The aim of this open-label clinical trial (resolve trial) was to assess the efficacy of 6-month lanreotide treatment, 120 mg, subcutaneously every 4 weeks in adpkd patients with symptomatic polycystic liver disease. |
Page: 1